JPMorgan analyst Brian Cheng lowered the firm’s price target on Immunovant (IMVT) to $33 from $37 and keeps an Overweight rating on the shares. The firm updated the company’s model.
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IMVT:
- 3 Best Stocks to Buy Now, 9/4/2025, According to Top Analysts
- Immunovant’s Batoclimab Shows Promising Results in Phase 2 Study for Graves’ Disease, Earning Buy Rating
- Immunovant’s Promising Clinical Data and Strategic Advancements Drive Buy Rating
- Immunovant Announces Promising Graves’ Disease Study Results
- Immunovant: 80% of patients demonstrate response in Graves’ disease trial